Susquehanna International Group, LLP Sage Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$7.02 - $13.08 $354,510 - $660,540	50,500 Added 91.32%	105,800 $762,000
Q2 2024 Aug 15, 2024	BUY	$10.58 - $17.9 $55,016 - $93,079	5,200 Added 10.38%	55,300 $600,000
Q1 2024 May 07, 2024	BUY	$18.62 - $26.95 $72,618 - $105,105	3,900 Added 8.44%	50,100 $938,000
Q4 2023 Feb 14, 2024	SELL	$17.1 - $22.26 $1.49 Million - $1.95 Million	-87,400 Reduced 65.42%	46,200 $1 Million
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $971,500 - $2.84 Million	58,000 Added 76.72%	133,600 $2.75 Million
Q2 2023 Aug 11, 2023	SELL	$40.65 - $59.54 $1.41 Million - $2.07 Million	-34,800 Reduced 31.52%	75,600 $3.55 Million
Q1 2023 May 16, 2023	BUY	$37.27 - $46.57 $3.8 Million - $4.75 Million	102,000 Added 1214.29%	110,400 $4.63 Million
Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $618,240 - $837,312	-19,200 Reduced 69.57%	8,400 $320,000
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $1.16 Million - $1.56 Million	-36,000 Reduced 56.6%	27,600 $1.08 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.